Fondaparinux for Management of Heparin-induced Thrombocytopenia after Cardiovascular Intervention: A systematic review

Vijaya R Bhatt, Sumit Dahal, Vivek Verma, Prem Shukla, Nabin Khanal, Ranjan Pathak, Smith Giri

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: The efficacy and safety of fondaparinux, an emerging therapeutic option for heparin-induced thrombocytopenia (HIT), remain unclear in cardiac surgery patients with HIT. Methods: Using several search criteria, we reviewed all cases of fondaparinux use in patients who developed HIT after any cardiovascular intervention and were indexed in MEDLINE by August 2014. Based on pre-specified criteria, cases were divided into confirmed HIT, probable HIT and possible HIT. The outcome of fondaparinux use in each group was compared using Chi-square test. Results: Of 43 total cases, 22 had confirmed HIT and 21 had possible HIT. Valve replacement or repair (39%) and heart transplant or ventricular assist device placement (21%) were the most common preceding cardiovascular interventions. Creatinine clearance <30 ml was present in 27% and 52% of confirmed and possible HIT respectively. Overall the risk of new thrombosis and bleeding with fondaparinux were 4.6% and 7% respectively, without any differences in the two subgroups. The majority (86%) of cases improved clinically; of the remainder patients, similar percentage of cases with possible HIT and confirmed HIT died (24% vs. 5%; p= 0.102). None of the deaths were attributed to HIT or complications of bleeding. Conclusion: Within the limitations of this study, the risk of thrombosis and bleeding with fondaparinux use in cardiac surgery patients with HIT are low and largely comparable to outcomes reported in literature with other agents.

Original languageEnglish (US)
Pages (from-to)82-86
Number of pages5
JournalCardiovascular and Hematological Agents in Medicinal Chemistry
Volume13
Issue number2
DOIs
StatePublished - Dec 1 2015

Fingerprint

Thrombocytopenia
Heparin
Heart-Assist Devices
Hemorrhage
fondaparinux
Thoracic Surgery
Thrombosis
Chi-Square Distribution
MEDLINE
Creatinine
Transplants
Safety

Keywords

  • Cardiovascular
  • Fondaparinux
  • Heparin-induced thrombocytopenia
  • Intervention

ASJC Scopus subject areas

  • Hematology
  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Fondaparinux for Management of Heparin-induced Thrombocytopenia after Cardiovascular Intervention : A systematic review. / Bhatt, Vijaya R; Dahal, Sumit; Verma, Vivek; Shukla, Prem; Khanal, Nabin; Pathak, Ranjan; Giri, Smith.

In: Cardiovascular and Hematological Agents in Medicinal Chemistry, Vol. 13, No. 2, 01.12.2015, p. 82-86.

Research output: Contribution to journalArticle

Bhatt, Vijaya R ; Dahal, Sumit ; Verma, Vivek ; Shukla, Prem ; Khanal, Nabin ; Pathak, Ranjan ; Giri, Smith. / Fondaparinux for Management of Heparin-induced Thrombocytopenia after Cardiovascular Intervention : A systematic review. In: Cardiovascular and Hematological Agents in Medicinal Chemistry. 2015 ; Vol. 13, No. 2. pp. 82-86.
@article{cc745cd3d7ea473285bc528198b8ff0b,
title = "Fondaparinux for Management of Heparin-induced Thrombocytopenia after Cardiovascular Intervention: A systematic review",
abstract = "Objectives: The efficacy and safety of fondaparinux, an emerging therapeutic option for heparin-induced thrombocytopenia (HIT), remain unclear in cardiac surgery patients with HIT. Methods: Using several search criteria, we reviewed all cases of fondaparinux use in patients who developed HIT after any cardiovascular intervention and were indexed in MEDLINE by August 2014. Based on pre-specified criteria, cases were divided into confirmed HIT, probable HIT and possible HIT. The outcome of fondaparinux use in each group was compared using Chi-square test. Results: Of 43 total cases, 22 had confirmed HIT and 21 had possible HIT. Valve replacement or repair (39{\%}) and heart transplant or ventricular assist device placement (21{\%}) were the most common preceding cardiovascular interventions. Creatinine clearance <30 ml was present in 27{\%} and 52{\%} of confirmed and possible HIT respectively. Overall the risk of new thrombosis and bleeding with fondaparinux were 4.6{\%} and 7{\%} respectively, without any differences in the two subgroups. The majority (86{\%}) of cases improved clinically; of the remainder patients, similar percentage of cases with possible HIT and confirmed HIT died (24{\%} vs. 5{\%}; p= 0.102). None of the deaths were attributed to HIT or complications of bleeding. Conclusion: Within the limitations of this study, the risk of thrombosis and bleeding with fondaparinux use in cardiac surgery patients with HIT are low and largely comparable to outcomes reported in literature with other agents.",
keywords = "Cardiovascular, Fondaparinux, Heparin-induced thrombocytopenia, Intervention",
author = "Bhatt, {Vijaya R} and Sumit Dahal and Vivek Verma and Prem Shukla and Nabin Khanal and Ranjan Pathak and Smith Giri",
year = "2015",
month = "12",
day = "1",
doi = "10.2174/1871525713666150911113811",
language = "English (US)",
volume = "13",
pages = "82--86",
journal = "Cardiovascular and Hematological Agents in Medicinal Chemistry",
issn = "1871-5257",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Fondaparinux for Management of Heparin-induced Thrombocytopenia after Cardiovascular Intervention

T2 - A systematic review

AU - Bhatt, Vijaya R

AU - Dahal, Sumit

AU - Verma, Vivek

AU - Shukla, Prem

AU - Khanal, Nabin

AU - Pathak, Ranjan

AU - Giri, Smith

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objectives: The efficacy and safety of fondaparinux, an emerging therapeutic option for heparin-induced thrombocytopenia (HIT), remain unclear in cardiac surgery patients with HIT. Methods: Using several search criteria, we reviewed all cases of fondaparinux use in patients who developed HIT after any cardiovascular intervention and were indexed in MEDLINE by August 2014. Based on pre-specified criteria, cases were divided into confirmed HIT, probable HIT and possible HIT. The outcome of fondaparinux use in each group was compared using Chi-square test. Results: Of 43 total cases, 22 had confirmed HIT and 21 had possible HIT. Valve replacement or repair (39%) and heart transplant or ventricular assist device placement (21%) were the most common preceding cardiovascular interventions. Creatinine clearance <30 ml was present in 27% and 52% of confirmed and possible HIT respectively. Overall the risk of new thrombosis and bleeding with fondaparinux were 4.6% and 7% respectively, without any differences in the two subgroups. The majority (86%) of cases improved clinically; of the remainder patients, similar percentage of cases with possible HIT and confirmed HIT died (24% vs. 5%; p= 0.102). None of the deaths were attributed to HIT or complications of bleeding. Conclusion: Within the limitations of this study, the risk of thrombosis and bleeding with fondaparinux use in cardiac surgery patients with HIT are low and largely comparable to outcomes reported in literature with other agents.

AB - Objectives: The efficacy and safety of fondaparinux, an emerging therapeutic option for heparin-induced thrombocytopenia (HIT), remain unclear in cardiac surgery patients with HIT. Methods: Using several search criteria, we reviewed all cases of fondaparinux use in patients who developed HIT after any cardiovascular intervention and were indexed in MEDLINE by August 2014. Based on pre-specified criteria, cases were divided into confirmed HIT, probable HIT and possible HIT. The outcome of fondaparinux use in each group was compared using Chi-square test. Results: Of 43 total cases, 22 had confirmed HIT and 21 had possible HIT. Valve replacement or repair (39%) and heart transplant or ventricular assist device placement (21%) were the most common preceding cardiovascular interventions. Creatinine clearance <30 ml was present in 27% and 52% of confirmed and possible HIT respectively. Overall the risk of new thrombosis and bleeding with fondaparinux were 4.6% and 7% respectively, without any differences in the two subgroups. The majority (86%) of cases improved clinically; of the remainder patients, similar percentage of cases with possible HIT and confirmed HIT died (24% vs. 5%; p= 0.102). None of the deaths were attributed to HIT or complications of bleeding. Conclusion: Within the limitations of this study, the risk of thrombosis and bleeding with fondaparinux use in cardiac surgery patients with HIT are low and largely comparable to outcomes reported in literature with other agents.

KW - Cardiovascular

KW - Fondaparinux

KW - Heparin-induced thrombocytopenia

KW - Intervention

UR - http://www.scopus.com/inward/record.url?scp=84953391311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953391311&partnerID=8YFLogxK

U2 - 10.2174/1871525713666150911113811

DO - 10.2174/1871525713666150911113811

M3 - Article

C2 - 26362274

AN - SCOPUS:84953391311

VL - 13

SP - 82

EP - 86

JO - Cardiovascular and Hematological Agents in Medicinal Chemistry

JF - Cardiovascular and Hematological Agents in Medicinal Chemistry

SN - 1871-5257

IS - 2

ER -